# Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

> **NCT00370851** · PHASE3 · COMPLETED · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 82 (actual)

## Conditions studied

- Retinal Disease

## Interventions

- **DRUG:** Avastin (Bevacizumab)

## Key facts

- **NCT ID:** NCT00370851
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-06
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2009-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370851, "Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00370851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*